

What Clinicians Want to Know: Addressing Community Oncologists' Questions About the Current and Future Role of Antibody-Drug Conjugates in the Management of Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following TROP2-directed antibody-drug conjugates is FDA approved in the first-line setting for patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy?
 - a. Sacituzumab govitecan
 - b. Datopotamab deruxtecan (Dato-DXd)**
 - c. Sacituzumab tirumotecan
 - d. Both sacituzumab govitecan and Dato-DXd

2. In the TROPION-Breast03 study, which of the following regimens is being compared to standard adjuvant therapy for patients with Stage I to III TNBC with residual invasive disease at surgical resection after neoadjuvant treatment?
 - a. Dato-DXd alone or with pembrolizumab
 - b. Dato-DXd alone or with durvalumab**
 - c. Dato-DXd with durvalumab
 - d. Dato-DXd with pembrolizumab
 - e. Dato-DXd monotherapy

3. Findings from the Phase III DESTINY-Breast11 study comparing T-DXd followed by docetaxel/trastuzumab/pertuzumab (THP) before surgery to standard neoadjuvant therapy for high-risk, HER2-positive localized breast cancer included which of the following efficacy outcomes?
 - a. A statistically significant improvement in pathologic complete response (pCR) rate and event-free survival (EFS) with T-DXd followed by THP
 - b. A statistically significant improvement in pCR rate and a positive trend in EFS with T-DXd followed by THP**
 - c. A statistically significant improvement in pCR rate and no difference in EFS with T-DXd followed by THP
 - d. A nonsignificant improvement in pCR rate and EFS with T-DXd followed by THP

4. Which of the following outcomes was reported in the Phase III TROPION-Breast02 trial comparing Dato-DXd to investigator's choice of chemotherapy for patients with previously untreated metastatic TNBC who were not eligible for immunotherapy?
 - a. Dato-DXd resulted in a similar objective response rate (ORR) but approximately doubled complete response (CR) rates
 - b. Dato-DXd approximately doubled the ORR and more than tripled CR rates**
 - c. Dato-DXd more than tripled the ORR and more than quadrupled CR rates

5. What is the recommended approach for a patient who experiences Grade 3 oral mucositis/stomatitis while receiving Dato-DXd despite appropriate prophylactic measures?
 - a. Continue Dato-DXd uninterrupted
 - b. Hold Dato-DXd until oral mucositis/stomatitis resolves to Grade ≤ 1 , then resume at the same dose
 - c. Hold Dato-DXd until oral mucositis/stomatitis resolves to Grade ≤ 1 , then resume at a reduced dose**
 - d. Permanently discontinue Dato-DXd